Please login to the form below
blood disorders
This page shows the latest blood disorders news and features for those working in and with pharma, biotech and healthcare.
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
developing medicines for malignant and non-malignant blood diseases for more than 20 years. ... For 20 years, we have remained committed to deepening our understanding of many benign and malignant blood disorders in order to better meet the urgent needs
Latest news
-
AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
Data from one real-world study, published as a pre-print on The Lancet server, contained analysis from over one million people assessing the incidence rates of the blood clotting disorders ... AZ added that the incidence of rare blood clot disorders were
-
BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
Along with our partners at Acceleron, we are committed to advancing our clinical programme for Reblozyl for patients living with anaemia-associated blood disorders,” he added. ... Rebloyzl is the first erythroid maturation agent to be approved in the EU
-
NICE recommends Ultomiris for NHS use in patients with rare blood disorders
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Alexion’s long-acting C5 complement inhibitor Ultomiris for NHS use in patients with rare blood disorders. ... PNH is a rare blood condition, wherein red blood cells
-
Versiti launches test for vaccine-related blood clot issues
Launch follows reports of very rare blood clots connected to J&J's vaccine. ... For more than 40 years, Versiti has been tirelessly researching cellular and molecular abnormalities in blood-related conditions including immune platelet disorders and HIT,"
-
New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
The EU regulator said that the review has currently not identified any specific risk factors, including age, gender or previous medical history of clotting disorders for the very rare blood clot ... In Canada, health authorities have also suspended use
More from news
Approximately 2 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been
-
Novo Nordisk awakens its ‘Sleeping Beauty’
The company is now projecting long-term improvements across its two main areas of haemophilia and growth hormone disorders, with confidence radiating into all quarters of its business. ... disorders field because we have access to this great science and
-
The challenges of making genomics a reality for patients
This approach is now being applied to diseases such as sickle cell, a group of inherited blood disorders.
-
The challenges of making genomics a reality for patients today, not tomorrow
This approach is now being applied to diseases such as sickle cell, a group of inherited blood disorders.
-
Deal Watch January 2018
enhance blood-brain barrier (BBB) penetration of antibody molecules via the transferrin receptor. ... Portfolio/pipeline in haemophilia and other rare blood disorders. Acquisition company. 11, 600.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Kiadis Pharma appoints Vincent Brichard to supervisory board
Kiadis has a focus on research, development and commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, including its lead product Atir. ... Atir achieved some extremely compelling clinical
-
Life keeps on growing with appointment of Kirsty Mead
blood disorders.
-
Cellerant appoints William Reed as VP clinical development
Will lead development of stem cell-based treatments for blood conditions and cancer. ... Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Products as portfolios: positioning immuno-oncology products
The cancer landscape is changing. Immunotherapeutic advances are driving significant improvements in treatment options for sufferers of many types of cancers and blood disorders. ... Within blood cancers, PD-(L) 1s and also monoclonal antibodies, in
-
Life keeps on growing
Previously Kirsty worked on MedEd accounts at Adventis Health. During her marketing degree she also spent a year at Baxter Healthcare as a marketing executive working on rare blood disorders.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- The UK’s new medicines pricing deal – opportunities and risks for pharma
- Biogen’s Aduhelm unlikely to get approval in Europe
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
